Resveratrol promotes osteogenesis of human mesenchymal stem cells by upregulating RUNX2 gene expression via the SIRT1/FOXO3A axis

Journal of Bone and Mineral Research

Volumn 26, Issue 10, 2011, Pages 2552-2563

  Tseng, Pei Chi ^a,b   Hou, Sheng Mou ^b   Chen, Ruey Jien ^a   Peng, Hsiao Wen ^a   Hsieh, Chi Fen ^a   Kuo, Min Liang ^a   Yen, Men Luh ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

Author keywords

FOXO3A; mesenchymal stem cells; osteogenesis; resveratrol; RUNX2; SIRT1

Indexed keywords

ESTROGEN; LEPTIN; OSTEOCALCIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; RESVERATROL; SIRTUIN 1; TRANSCRIPTION FACTOR FKHRL1; TRANSCRIPTION FACTOR RUNX2;

ADIPOGENESIS; ARTICLE; BINDING SITE; BONE DEVELOPMENT; CELL LINEAGE; COMPLEX FORMATION; CONTROLLED STUDY; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MESENCHYMAL STEM CELL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION;

BASE SEQUENCE; CHROMATIN IMMUNOPRECIPITATION; CORE BINDING FACTOR ALPHA 1 SUBUNIT; DNA PRIMERS; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; MESENCHYMAL STEM CELLS; OSTEOGENESIS; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; RECEPTORS, ESTROGEN; SIRTUIN 1; STILBENES; UP-REGULATION;

EID: 80053214204     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.460     Document Type: Article

References (47)

1. Couzin J,. Estrogen research: the great estrogen conundrum. Science. 2003; 302: 1136-38.
2. Gehm BD, McAndrews JM, Chien PY, Jameson JL,. Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc Natl Acad Sci USA. 1997; 94: 14138-43. (Pubitemid 28009723)
3. Sakamoto T, Horiguchi H, Oguma E, Kayama F,. Effects of diverse dietary phytoestrogens on cell growth, cell cycle and apoptosis in estrogen-receptor- positive breast cancer cells. J Nutr Biochem. 2010; 21: 856-64.
4. Cao Z, Li Y,. Potent induction of cellular antioxidants and phase 2 enzymes by resveratrol in cardiomyocytes: protection against oxidative and electrophilic injury. Eur J Pharmacol. 2004; 489: 39-48. (Pubitemid 38520069)
5. Su JL, Yang CY, Zhao M, Kuo ML, Yen ML,. Forkhead proteins are critical for bone morphogenetic protein-2 regulation and anti-tumor activity of resveratrol. J Biol Chem. 2007; 282: 19385-98. (Pubitemid 47100112)
6. Rahman I,. Dietary polyphenols mediated regulation of oxidative stress and chromatin remodeling in inflammation. Nutr Rev. 2008; 66 (Suppl 1): S42-45.
7. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, Zipkin RE, Chung P, Kisielewski A, Zhang LL, Scherer B, Sinclair DA,. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature. 2003; 425: 191-6. (Pubitemid 37150899)
8. Knutson MD, Leeuwenburgh C,. Resveratrol and novel potent activators of SIRT1: effects on aging and age-related diseases. Nutr Rev. 2008; 66: 591-6.
9. Dai Z, Li Y, Quarles LD, Song T, Pan W, Zhou H, Xiao Z,. Resveratrol enhances proliferation and osteoblastic differentiation in human mesenchymal stem cells via ER-dependent ERK1/2 activation. Phytomedicine. 2007; 14: 806-14. (Pubitemid 350017876)
10. Mizutani K, Ikeda K, Kawai Y, Yamori Y,. Resveratrol attenuates ovariectomy-induced hypertension and bone loss in stroke-prone spontaneously hypertensive rats. J Nutr Sci Vitaminol (Tokyo). 2000; 46: 78-83. (Pubitemid 30397400)
11. Backesjo CM, Li Y, Lindgren U, Haldosen LA,. Activation of Sirt1 decreases adipocyte formation during osteoblast differentiation of mesenchymal stem cells. Cells Tissues Organs. 2009; 189: 93-7.
12. Zhou H, Shang L, Li X, Zhang X, Gao G, Guo C, Chen B, Liu Q, Gong Y, Shao C,. Resveratrol augments the canonical Wnt signaling pathway in promoting osteoblastic differentiation of multipotent mesenchymal cells. Exp Cell Res. 2009; 315: 2953-62.
13. Song LH, Pan W, Yu YH, Quarles LD, Zhou HH, Xiao ZS,. Resveratrol prevents CsA inhibition of proliferation and osteoblastic differentiation of mouse bone marrow-derived mesenchymal stem cells through an ER/NO/cGMP pathway. Toxicol In Vitro. 2006; 20: 915-22.
14. Haigis MC, Guarente LP,. Mammalian sirtuins-emerging roles in physiology, aging, and calorie restriction. Genes Dev. 2006; 20: 2913-21. (Pubitemid 44771725)
15. Milne JC, Lambert PD, Schenk S, Carney DP, Smith JJ, Gagne DJ, Jin L, Boss O, Perni RB, Vu CB, Bemis JE, Xie R, Disch JS, Ng PY, Nunes JJ, Lynch AV, Yang H, Galonek H, Israelian K, Choy W, Iffland A, Lavu S, Medvedik O, Sinclair DA, Olefsky JM, Jirousek MR, Elliott PJ, Westphal CH,. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature. 2007; 450: 712-16. (Pubitemid 350207685)
16. Luo J, Nikolaev AY, Imai S, Chen D, Su F, Shiloh A, Guarente L, Gu W,. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell. 2001; 107: 137-48. (Pubitemid 33035941)
17. Vaziri H, Dessain SK, Ng Eaton E, Imai SI, Frye RA, Pandita TK, Guarente L, Weinberg RA,. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell. 2001; 107: 149-59. (Pubitemid 33035942)
18. Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y, Tran H, Ross SE, Mostoslavsky R, Cohen HY, Hu LS, Cheng HL, Jedrychowski MP, Gygi SP, Sinclair DA, Alt FW, Greenberg ME,. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science. 2004; 303: 2011-15. (Pubitemid 38393275)
19. Jeong J, Juhn K, Lee H, Kim SH, Min BH, Lee KM, Cho MH, Park GH, Lee KH,. SIRT1 promotes DNA repair activity and deacetylation of Ku70. Exp Mol Med. 2007; 39: 8-13. (Pubitemid 46356001)
20. Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Frye RA, Mayo MW,. Modulation of NF-κB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J. 2004; 23: 2369-80. (Pubitemid 38954844)
21. Libert S, Cohen D, Guarente L,. Neurogenesis directed by Sirt1. Nat Cell Biol. 2008; 10: 373-4.
22. Kim MJ, Ahn K, Park SH, Kang HJ, Jang BG, Oh SJ, Oh SM, Jeong YJ, Heo JI, Suh JG, Lim SS, Ko YJ, Huh SO, Kim SC, Park JB, Kim J, Kim JI, Jo SA, Lee JY,. SIRT1 regulates tyrosine hydroxylase expression and differentiation of neuroblastoma cells via FOXO3a. FEBS Lett. 2009; 583: 1183-8.
23. Greer EL, Brunet A,. FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene. 2005; 24: 7410-25. (Pubitemid 41637981)
24. van der Horst A, Burgering BM,. Stressing the role of FoxO proteins in lifespan and disease. Nat Rev Mol Cell Biol. 2007; 8: 440-50. (Pubitemid 46809159)
25. Vogt PK, Jiang H, Aoki M,. Triple layer control: phosphorylation, acetylation and ubiquitination of FOXO proteins. Cell Cycle. 2005; 4: 908-13. (Pubitemid 41359756)
26. Takada I, Suzawa M, Matsumoto K, Kato S,. Suppression of PPAR transactivation switches cell fate of bone marrow stem cells from adipocytes into osteoblasts. Ann N Y Acad Sci. 2007; 1116: 182-95. (Pubitemid 350274329)
27. Franceschi RT, Xiao G,. Regulation of the osteoblast-specific transcription factor, Runx2: responsiveness to multiple signal transduction pathways. J Cell Biochem. 2003; 88: 446-54. (Pubitemid 36158266)
28. Komori T,. Regulation of osteoblast differentiation by transcription factors. J Cell Biochem. 2006; 99: 1233-9.
29. Shockley KR, Lazarenko OP, Czernik PJ, Rosen CJ, Churchill GA, Lecka-Czernik B,. PPARγ2 nuclear receptor controls multiple regulatory pathways of osteoblast differentiation from marrow mesenchymal stem cells. J Cell Biochem. 2009; 106: 232-46.
30. Picard F, Kurtev M, Chung N, Topark-Ngarm A, Senawong T, Machado De Oliveira R, Leid M, McBurney MW, Guarente L,. Sirt1 promotes fat mobilization in white adipocytes by repressing PPARγ. Nature. 2004; 429: 771-6. (Pubitemid 38833129)
31. Jeon MJ, Kim JA, Kwon SH, Kim SW, Park KS, Park SW, Kim SY, Shin CS,. Activation of peroxisome proliferator-activated receptor-gamma inhibits the Runx2-mediated transcription of osteocalcin in osteoblasts. J Biol Chem. 2003; 278: 23270-7. (Pubitemid 36830140)
32. Tou L, Quibria N, Alexander JM,. Transcriptional regulation of the human Runx2/Cbfa1 gene promoter by bone morphogenetic protein-7. Mol Cell Endocrinol. 2003; 205: 121-9. (Pubitemid 37297358)
33. Abeyta MJ, Clark AT, Rodriguez RT, Bodnar MS, Pera RA, Firpo MT,. Unique gene expression signatures of independently-derived human embryonic stem cell lines. Hum Mol Genet. 2004; 13: 601-8. (Pubitemid 38386590)
34. Tran H, Brunet A, Grenier JM, Datta SR, Fornace AJ Jr, DiStefano PS, Chiang LW, Greenberg ME,. DNA repair pathway stimulated by the forkhead transcription factor FOXO3a through the Gadd45 protein. Science. 2002; 296: 530-4. (Pubitemid 34408672)
35. Escande C, Chini CC, Nin V, Dykhouse KM, Novak CM, Levine J, van Deursen J, Gores GJ, Chen J, Lou Z, Chini EN,. Deleted in breast cancer-1 regulates SIRT1 activity and contributes to high-fat diet-induced liver steatosis in mice. J Clin Invest. 2010; 120: 545-58.
36. Yen BL, Chang CJ, Liu KJ, Chen YC, Hu HI, Bai CH, Yen ML,. Brief report: Human embryonic stem cell-derived mesenchymal progenitors possess strong immunosuppressive effects toward natural killer cells as well as T lymphocytes. Stem Cells. 2009; 27: 451-6.
37. Barberi T, Willis LM, Socci ND, Studer L,. Derivation of multipotent mesenchymal precursors from human embryonic stem cells. PLoS Med. 2005; 2: e161.
38. Olivier EN, Rybicki AC, Bouhassira EE,. Differentiation of human embryonic stem cells into bipotent mesenchymal stem cells. Stem Cells. 2006; 24: 1914-22. (Pubitemid 44474167)
39. - differentiated human ESCs. Stem Cells. 2007; 25: 425-36. (Pubitemid 46232798)
40. Rosen CJ,. Bone remodeling, energy metabolism, and the molecular clock. Cell Metab. 2008; 7: 7-10.
41. Deschaseaux F, Sensebe L, Heymann D,. Mechanisms of bone repair and regeneration. Trends Mol Med. 2009; 15: 417-29.
42. van der Heide LP, Smidt MP,. Regulation of FoxO activity by CBP/p300-mediated acetylation. Trends Biochem Sci. 2005; 30: 81-6. (Pubitemid 40187300)
43. Kawamura N, Kugimiya F, Oshima Y, Ohba S, Ikeda T, Saito T, Shinoda Y, Kawasaki Y, Ogata N, Hoshi K, Akiyama T, Chen WS, Hay N, Tobe K, Kadowaki T, Azuma Y, Tanaka S, Nakamura K, Chung UI, Kawaguchi H,. Akt1 in osteoblasts and osteoclasts controls bone remodeling. PLoS One. 2007; 2: e1058.
44. Almeida M, Han L, Martin-Millan M, O'Brien CA, Manolagas SC,. Oxidative stress antagonizes Wnt signaling in osteoblast precursors by diverting β-catenin from T cell factor- to forkhead box O-mediated transcription. J Biol Chem. 2007; 282: 27298-305. (Pubitemid 47501978)
45. Almeida M, Ambrogini E, Han L, Manolagas SC, Jilka RL,. Increased lipid oxidation causes oxidative stress, increased peroxisome proliferator-activated receptor-gamma expression, and diminished pro-osteogenic Wnt signaling in the skeleton. J Biol Chem. 2009; 284: 27438-48.
46. Manolagas SC, Almeida M,. Gone with the Wnts: β-catenin, T-cell factor, forkhead box O, and oxidative stress in age-dependent diseases of bone, lipid, and glucose metabolism. Mol Endocrinol. 2007; 21: 2605-14. (Pubitemid 350035144)
47. Ambrogini E, Almeida M, Martin-Millan M, Paik JH, Depinho RA, Han L, Goellner J, Weinstein RS, Jilka RL, O'Brien CA, Manolagas SC,. FoxO-mediated defense against oxidative stress in osteoblasts is indispensable for skeletal homeostasis in mice. Cell Metab. 2010; 11: 136-46.